Avinger Inc (Avinger) designs, develops, manufactures, and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). The company develops products using its Lumivascular platform, an intravascular image-guided system that comprises the Lightbox imaging console, the Pantheris family of atherectomy devices and the Ocelot family of catheters.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Avinger’s research and development initiatives are focused on improving and enhancing the Lumivascular platform by integrating OCT intravascular imaging onto therapeutic catheters. The company's objectives include product line improvements and extensions, developing next-generation CTO crossing devices, seeking additional regulatory clearances for expanded treatment indications, and improving software and user interface based on feedback from healthcare providers. Avinger collaborates with third-party contractors and medical experts to supplement its internal R&D resources. The R&D unit of Avinger is responsible for the ongoing research and development activities aimed at improving the Lumivascular platform, developing new products, and expanding treatment indications. The unit manages collaborations with third-party contractors and medical experts to enhance the company's R&D capabilities. As of December 31, 2023, Avinger held 64 issued and allowed US patents, one US pending provisional application, 18 U.S. utility patent applications, and three PCT applications pending. The company also had 83 issued and allowed patents outside of the US and 22 pending patent applications in various countries. The company held six registered U.S. trademarks, one registered trademark in Europe, and one in the UK, along with an International Registration under the Madrid Protocol. In FY2023, the company spent US$4.5 million on its R&D activities, which grew 3.4% YoY.